2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study
Yegya-Raman N, Plastaras J, Wright C, Chelius M, Zhang S, Baron J, Hubbeling H, Sim A, Robinson T, Jain M, Imber B, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix C, Gunther J, Fang P, Wu S, Dabaja B, Yang J, Chew J, Braunstein S, Sinha S, Delinger N, Sun S, Terezakis S, Sakthivel G, Constine L, Chowdhry A, Reagan P, Burke S, Tseng Y, LaRiviere M, Maity A, Schuster S, Chong E, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. Blood Advances 2025, 9: 3293-3303. PMID: 40203192, DOI: 10.1182/bloodadvances.2025015855.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeSuperior progression-free survivalProgression-free survivalB-cell lymphomaCytokine release syndromeAssociated with superior progression-free survivalOverall survivalTwo-year progression-free survivalChimeric antigen receptor T cellsLactate dehydrogenaseRelapsed/refractory B-cell lymphomaLactate dehydrogenase normalizationAmerican Society for TransplantationT-cell therapyBaseline lactate dehydrogenaseMedian Follow-UpRetrospectively reviewed patientsAdvanced-stage diseaseHigh-risk cohortAxicabtagene ciloleucelBrexucabtagene autoleucelSystemic therapyMulticenter studyT cells
2024
Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, Manyam G, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli M, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray J, Herbst R, Wistuba I, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee J, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clinical Cancer Research 2024, 30: 1655-1668. PMID: 38277235, PMCID: PMC11016892, DOI: 10.1158/1078-0432.ccr-23-0251.Peer-Reviewed Original ResearchConceptsChromosome copy-number variationsOverall survivalMultiplex immunofluorescenceMulti-omics analysisAssociated with superior progression-free survivalNCounter PanCancer Immune Profiling PanelSquamous cell lung cancer patientsSuperior progression-free survivalTreated with nivolumab monotherapyAssociated with worse overall survivalNon-small cell carcinomaAssociated with worse survivalCell lung cancer patientsCold immune microenvironmentProgression-free survivalImmune Profiling PanelRegulatory T cellsPhase III trialsResponse to ICIImmune cell infiltrationHigher immune scoresImmune cell densityLung cancer patientsWhole-exome sequencingImmune gene expression profiles
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply